These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15891885)

  • 1. CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation.
    Willems A; Schoonooghe S; Eeckhout D; De Jaeger G; Grooten J; Mertens N
    Cancer Immunol Immunother; 2005 Nov; 54(11):1059-71. PubMed ID: 15891885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
    Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
    Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
    Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
    Int J Cancer; 1999 Jan; 80(1):138-44. PubMed ID: 9935244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study.
    Pfosser A; Brandl M; Salih H; Grosse-Hovest L; Jung G
    Int J Cancer; 1999 Feb; 80(4):612-6. PubMed ID: 9935165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
    Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
    Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy.
    Jung G; Brandl M; Eisner W; Fraunberger P; Reifenberger G; Schlegel U; Wiestler OD; Reulen HJ; Wilmanns W
    Int J Cancer; 2001 Jan; 91(2):225-30. PubMed ID: 11146449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
    Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
    J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
    Haas C; Strauss G; Moldenhauer G; Iorio RM; Schirrmacher V
    Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.
    Karches CH; Benmebarek MR; Schmidbauer ML; Kurzay M; Klaus R; Geiger M; Rataj F; Cadilha BL; Lesch S; Heise C; Murr R; Vom Berg J; Jastroch M; Lamp D; Ding J; Duewell P; Niederfellner G; Sustmann C; Endres S; Klein C; Kobold S
    Clin Cancer Res; 2019 Oct; 25(19):5890-5900. PubMed ID: 31285373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine.
    Fournier P; Aigner M; Schirrmacher V
    Int J Oncol; 2010 Nov; 37(5):1203-17. PubMed ID: 20878068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.
    Kufer P; Mack M; Gruber R; Lutterbüse R; Zettl F; Riethmüller G
    Cancer Immunol Immunother; 1997; 45(3-4):193-7. PubMed ID: 9435872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
    Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
    J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
    Renner C; Jung W; Sahin U; Denfeld R; Pohl C; Trümper L; Hartmann F; Diehl V; van Lier R; Pfreundschuh M
    Science; 1994 May; 264(5160):833-5. PubMed ID: 8171337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor antigen-dependent and tumor antigen-independent activation of antitumor activity in T cells by a bispecific antibody-modified tumor vaccine.
    Fournier P; Schirrmacher V
    Clin Dev Immunol; 2010; 2010():423781. PubMed ID: 21403859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to implement bispecific antibody treatment of ovarian carcinoma.
    Canevari S; Mezzanzanica D; Mazzoni A; Negri DR; Figini M; Ramakrishna V; Bolis G; Colnaghi MI
    Cancer Immunol Immunother; 1997; 45(3-4):187-9. PubMed ID: 9435870
    [No Abstract]   [Full Text] [Related]  

  • 17. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation.
    Demanet C; Brissinck J; De Jonge J; Thielemans K
    Blood; 1996 May; 87(10):4390-8. PubMed ID: 8639800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
    Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
    Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
    da Costa L; Renner C; Hartmann F; Pfreundschuh M
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
    J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.